Tainted Product: DigiPath Looks to Add Quality Assurance to Cannabis
Richard Battle
July 6th, 2015
Uncategorized
Cannabis may seem like a tightly controlled market on the surface, but lax state laws, inconsistent lab practices, and inaccurate test results have introduced dangers to users. In a joint investigation, Oregon Live and the Oregonian tested ten popular marijuana concentrates in Oregon and found that nearly all of them contained pesticides. A total of 14 chemicals were found in eight of the samples, including six that the federal government considers carcinogenic.
Traditional pharmaceutical companies, like Pfizer Inc. (NYSE: PFE) or Merck & Co. (NYSE: MRK), are required to undergo extensive clinical trials to evaluate the safety of their products, while production is subject to rigorous quality and manufacturing rules, known as CGMP standards. Marijuana and marijuana-infused edibles manufacturers aren’t subjected to nearly as rigorous standards, despite the high risk for contamination and other issues.
Under most states’ regulations, to the extent they exist, companies developing cannabis products must simply submit samples to state-certified independent laboratories for a small fee and obtain a certificate showing that the samples are free from harmful chemicals. The problem is that the sample is just that – a sample, and state rules don’t cover many common pesticides used in marijuana cultivation – even known toxic chemicals. Moreover, testing lab results themselves are often inaccurate.
Evolving State Rules
Many states that have approved medical and recreational marijuana have been slow to adopt appropriate testing standards to ensure product quality. In fact, Colorado had no protocols in place when the state first legalized the drug. It wasn’t until a series of overdoses made national news that the state established a testing program to ensure product safety. Similarly, Washington State didn’t introduce its testing requirements until 2013 when recreational cannabis became legal.
The good news is that states are beginning to realize the scope of problems associated with both safety and labeling accuracy. Oregon, Massachusetts, and most new medical marijuana states have at least begun including lab certifications in their regulations. Industry organizations like the Association of Commercial Cannabis Laboratories (“ACCL”) also promise to help produce consistent, accurate results using a common set of criteria.
The bad news is that testing rules have been slow to be established and progress, and there is actually a shortage of cannabis testing facilities nationwide. For instance, the only private lab approved to test cannabis in New Mexico closed its doors, leaving producers empty-handed when it comes to complying with the state’s quality assurance standards. Some in New Mexico have urged the state to pursue government testing at its $86 million taxpayer-funded laboratory that is currently responsible for a wide array of other tests.
Cleaning Up the Industry
DigiPath Inc. (OTC: DIGP), one of the few publicly-traded cannabis companies, recently opened one of just three certified cannabis testing laboratories in the State of Nevada. Led by Dr. Cindy Orser, Ph.D., a 20-year biotech and diagnostic industry veteran, the company has spared no expenses in equipping the lab with ultra-sensitive Agilent Technologies Inc. (NYSE: A) instrumentation that enables both highly-accurate and replicable testing results in just 48 hours.
Samples are visually inspected for foreign matter and then tested for the presence of microbes, mycotoxins, heavy metals, pesticides, and solvents used in the making of cannabis-based concentrates. In addition, the cannabis flower is analyzed for moisture levels in order to ensure that they were properly cured. A detailed cannabinoid and terpenoid potency profile is then provided so patients, caregivers, and dispensary staff can match the product to the patient.
Dr. Orser leads these efforts on behalf of DigiPath, serving as the liaison between cannabis providers and regulatory agencies, including the FDA and CDC, as well as working in academia in several key roles. In addition to her work, she holds 18 patents and has authored 41 peer-reviewed publications, after earning her Ph.D. from the University of California Berkeley and BS in Botany from Montana State University.
Looking Ahead
The cannabis testing industry is projected to be worth about $850 million in size, according to GreenWave Advisors, with a limited number of publicly traded companies in the space, including DigiPath, CannLabs Inc. (OTC: CANL), and Pazoo Inc. (OTC: PZOO). With awareness of testing deficiencies rising among consumers and regulators, the industry could see stricter regulations on the horizon that could help the testing industry expand.
For more information, visit www.digipath.com. To learn more about it’s recently opened Nevada-based laboratory and potential expansion opportunities ahead visit www.digipathlabs.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Richard Battle
Mr. Battle has over a decade of experience in the financial markets as both a private investor and financial journalist.Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products.
Jacksam/Convectium designs and markets proprietary automated vape, POD and cartridge filling/capping equipment for the cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
